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Background: Clonidine has been shown to be a potent neuroprotectant by acting at α2 receptors on glutamatergic 
neurons to inhibit the release of glutamate. The aim of this study is to investigate the effects of clonidine on the 
activity of EAAT3 that can regulate extracellular glutamate. 
Methods: EAAT3 was expressed in the Xenopus oocytes. Using a two­electrode voltage clamp, membrane currents 
were recorded after application of 30 μM L­glutamate both in the presence and absence of various concentrations 
of clonidine. To determine the effects of clonidine on the Km and Vmax of EAAT3 and the reversibility of clonidine 
effects, membrane currents were recorded after the application of various concentrations of L­glutamate both in the 
presence and absence of 1.50 × 10
-7 M clonidine. 
Results: Clonidine reduced the EAAT3 responses to L­glutamate in a concentration­dependent manner. This 
inhibition was statistically significant at higher concentrations than at the clinically relevant range. Clonidine at 1.50 
× 10
-7 M reduced the Vmax, but did not affect the Km of EAAT3 for L­glutamate. 
Conclusions: These results suggest that the direct inhibition of EAAT3 activity is not related to the sedation effect 
of clonidine and that the clonidine­induced reduction of EAAT3 activity provides additional data for the possible 
involvement of glutamatergic hyperactivity in the proconvulsant effect of clonidine. (Korean J Anesthesiol 2012; 62: 
266­271)
Key Words:  Clonidine, Glutamate, Glutamate transporters.
Effects of clonidine on the activity of the rat glutamate 
transporter EAAT3 expressed in Xenopus oocytes
Jae Hee Woo, Jong In Han, Hee Jung Baik, and Heeseung Lee
Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Seoul, Korea 
Received: October 10, 2011.  Accepted: October 15, 2011.
Corresponding author: Jong In Han, M.D., Ph.D., Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans 
University, 119, Mok-dong, Yangcheon-gu, Seoul 158-710, Korea. Tel: 82-2-2650-5559, Fax: 82-2-2655-2924, E-mail: hanji@ewha.ac.kr
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC267 www.ekja.org
Korean J Anesthesiol Woo, et al.
Introduction
L­Glutamate is the major excitatory neurotransmitter in 
the central nervous system (CNS) and plays a dominant role 
in central excitatory neurotransmission involved in neuronal 
survival, synaptogenesis, neuronal plasticity, learning and 
memory processes. Glutamate is found naturally in millimolar 
levels in the brain; however, it can cause excitotoxic neuronal 
damage at high extracellular concentrations [1]. Extracellular 
glutamate concentrations are maintained within physiological 
levels by glutamate transporters (also known as excitatory amino 
acid transporters, EAATs) because no extracelluar enzymes 
exist for the breakdown of glutamate [2]. Five major subtypes 
of EAATs have been identified. EAAT1 is present in glial cells 
throughout the CNS and at high levels in the Bergmann glia 
of the cerebellum. EAAT2 is almost exclusively glial, and is 
widespread and highly abundant throughout the forebrain, 
cerebellum and spinal cord. The EAAT3 and EAAT4 are present 
predominantly in neurons; EAAT3 is selectively enriched in 
the neurons of the hippocampus, basal ganglia, cerebellum, 
and olfactory bulb, whereas EAAT4 is predominantly localized 
to cerebellar Purkinje cells, with low levels of expression 
also present in the forebrain. EAAT5 is present in the rod 
photoreceptor and bipolar cells of the retina [3,4].
Astroglial glutamate transporters (EAAT1 and EAAT2) are the 
predominant pathway for the synaptic inactivation of glutamate 
in the forebrain. Although there is little evidence for presynaptic 
or postsynaptic inactivation of glutamate by neuronal 
transporters, at least in the hippocampus and cerebral cortex, 
glutamate uptake could be primarily neuronal because many 
of the synapses are not surrounded by astrocytic processes in 
these brain areas [5]. Several studies have reported that EAAT3 
activity increases with volatile anesthetics [6], propofol [7], 
lidocaine [8] and benzodiazepines [9], which could explain the 
anesthetic actions and the neuroprotective and antiepileptic 
effects of these drugs. 
Clonidine, a selective α2­adrenergic receptor agonist, 
exhibits anesthetic, sedative, anxiolytic, sympatholytic and 
analgesic properties in clinical practice [10]. It has also been 
shown that clonidine is a potent neuroprotector in various 
cerebral hypoxia­ischemia models in which the accumulation 
of high concentrations of glutamate in the extracellular space 
is a key pathologic event and that α2­adrenergic receptors are 
important in mediating clonidine­induced neuroprotection 
[11,12]. It has been reported that activation of α2­adrenergic 
receptors located on the nerve terminals of the glutamatergic 
neurons inhibit the release of glutamate [13]. Considering these 
results, the sedative, anesthetic, and analgesic actions as well 
as the neuroprotective effect of clonidine may be implicated in 
the glutamatergic system, including the effect on the activity 
of the glutamate transporter. However, it is not known whether 
clonidine can affect the EAAT3 activity. The aim of this study is 
to investigate the effects of clonidine on the activity of EAAT3 
proteins that can regulate extracellular glutamate using Xenopus 
oocytes.
Materials and Methods
Oocyte preparation and injection
Mature female Xenopus	laevis frogs were purchased from 
Kato S Science (Chiba, Japan) and fed regular frog brittle twice 
weekly. All reagents, unless specified below, were obtained 
from Sigma (St. Louis, MO, USA). For removal of the oocytes, 
the frogs were anesthetized in 500 ml 0.2% 3­aminobenzoic 
acid ethyl ester in water until unresponsive to painful stimuli 
(toe pinching) and underwent surgery on ice. The oocytes 
were surgically retrieved and placed immediately in a calcium­
free OR­2 solution. The OR­2 solution comprised (in mM): 
82.5 NaCl, 2 KCl, 1 MgCl2, 5 HEPES with pH adjusted to 
7.5. The oocytes were defolliculated with gentle shaking for 
approximately 2 hours in a calcium­free OR­2 solution including 
0.1% collagenase type Ia. The oocytes were then incubated 
in a modified Barth's solution at 16
oC for one day before the 
injection of EAAT3 mRNA. The modified Barth's solution 
comprised (in mM): 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.41 CaCl2, 0.82 
MgSO4, 0.3 Ca (NO3)2, 0.1 gentamicin and 15 HEPES, with pH 
adjusted to 7.5. 
The rat EAAT3 complementary DNA (cDNA) construct was 
provided by Dr. Mattias A. Hediger (Brigham and Women's 
Hospital, Harvard Institutes of Medicine, Boston, MA, USA). The 
cDNA was subcloned in a commercial vector (BluescriptSKm). 
The plasmid DNA was linearized with a restriction enzyme 
(Not I) and mRNA was synthesized in vitro with a commercially 
available kit (Ambion, Austin, TX, USA). The resulting mRNA 
was quantified spectrophotometrically and diluted in sterile 
water. This mRNA was used for the cytoplasmic injection of 
oocytes in a concentration of 40 ng/ 40 nl by using an automated 
microinjector (Nanoliter 2000; World Precision Instruments, 
Sarasota, FL, USA). The oocytes were then incubated at 16
oC 
in a modified Barth's solution for three days before voltage­
clamping experiments.
Electrophysiological recordings
Experiments were performed at room temperature (appro­
ximately 21-23
oC). A single oocyte was placed in a recording 
chamber that was < 1 ml in volume and was perfused with 5 
ml Tyrode's solution/min. The Tyrode's solution comprised 
(in mM): 150 NaCl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 dextrose and 10 268 www.ekja.org
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HEPES, with pH adjusted to 7.5. Clamping microelectrodes were 
pulled from capillary glass (Single­Barrel Standard Borosilicate 
Glass Tubing, World Precision Instruments) on a micropipette 
puller (Temperature controlled pipette puller PIP5; HEKA 
Instruments Inc., Bellmore, New York, USA). The tips were 
broken at a diameter of approximately 10 μm and filled with 
3 M KCl, obtaining a resistance of 1-3 MΩ. The oocytes were 
voltage­clamped using a two­electrode voltage clamp amplifier 
(OC725­A; Warner Corporation, New Haven, CT, USA) that was 
connected to a data acquisition and analysis system running 
on a personal computer. The acquisition system consisted of 
a DAS­8A/D conversion board (Keithley­Metrabyte, Taunton, 
MA, USA). Analyses were performed with pCLAMP7 software 
(Axon Instruments, Foster City, CA, USA). All measurements 
were performed at a holding potential of -70 mV. The oocytes 
that did not show a stable holding current of less than 1 μA were 
excluded from analysis. L­Glutamate was diluted in Tyrode's 
solution and superfused over the oocyte for 25 s (5 ml/min). 
The L­Glutamate­induced inward currents were sampled at 
125 Hz for 1 min: 5 s of baseline, 25 s of L­glutamate application 
and 30 s of washing with Tyrode's solution. The glutamate­
induced peak currents were calculated to reflect the amount 
of glutamate transported. We used 30 μM L­glutamate, unless 
indicated otherwise, in this study because the value of the 
pharmacokinetic parameter Km of EAAT3 for L­glutamate was 
shown to be 27-30 μM in previous studies [6,14].
Administration of experimental chemicals
Clonidine hydrochloride was dissolved in dimethyl sulfoxide 
and then diluted by Tyrode’s solution to the appropriate final 
concentrations (0.2, 0.5, 2, 4, 7, 10, 20, 40 or 50 ng/ml that 
corresponds to 7.50 × 10
-10, 1.88 × 10
-9, 7.50 × 10
-9, 1.50 × 10
-8, 
2.63 × 10
-8, 3.75 × 10
-8, 7.50 × 10
-8, 1.50 × 10
-7 or 1.88 × 10
-7 M), 
which include clinically relevant plasma concentrations. In the 
control experiments, the oocytes were perfused with Tyrode’s 
solution for 4 min before the application of Tyrode’s solution 
containing L­glutamate for the electrophysiological recording. 
In the clonidine­treated group, the oocytes were perfused with 
Tyrode’s solution for the first minute for stabilization followed 
by Tyrode’s solution containing clonidine for 3 min before the 
application of Tyrode’s solution containing L­glutamate for 
the electrophysiological recording. To determine the effects of 
clonidine on the Km and Vmax of EAAT3 and the reversibility 
of clonidine effects, the responses to serial concentrations of 
L­glutamate (3, 10, 30, 100, 300 and 1,000 μM) were assayed, 
the oocytes were then treated with 1.50 × 10
-7 M clonidine and 
the responses were again recorded. For the stabilization, the 
oocytes were perfused with Tyrode’s solution for 4 min before 
the second and third measurements. 
Data analysis
Responses are reported as mean ± SEM. Each experimental 
condition was performed with the oocytes from at least three 
different frogs. Since the expression level of the transporter 
proteins in the oocytes of different batches may vary, variability 
in responses among the batches of oocytes is common. Thus, 
the responses were normalized to the mean value of the same­
day controls for each batch. Similarly, in the reversibility 
experiments, the responses were normalized to the responses of 
the same oocytes to 1 mM glutamate under control conditions 
(before the clonidine treatment). This concentration of 
glutamate was the highest concentration used to induce EAAT3 
activity and this normalization allowed us to pool together 
data from different batches of oocytes for analysis. Statistical 
analysis was performed using the Student's t­test, one­way 
repeated measures analysis of variance (ANOVA) or one way 
ANOVA followed by the Tukey multiple comparison test (SPSS 
version 18.0, SPSS Inc., an IBM Company, Chicago, IL, USA) as 
appropriate. Differences were considered significant at P < 0.05. 
Dose­response curves were prepared and IC50 was calculated 
using GraphPad Prism version 5.0 (GraphPad Software, San 
Diego, CA, USA). 
Results
The oocytes injected with EAAT3 mRNA showed inward 
currents after L­glutamate application (Fig. 1), whereas the 
Fig. 1. Dose-response of clonidine inhibition of EAAT3 responses 
to 30 μM L-glutamate. The IC50 value for this inhibition was 2.72 × 
10
-8 M. The upper graphs show typical current traces induced by the 
application of 30 μM L-glutamate. Data show the means ± SEM (n = 
25-50 in each data point). *P < 0.05 compared to control. 269 www.ekja.org
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uninjected oocytes were unresponsive to L­glutamate (data not 
shown). This current has been shown to be mediated via EAAT3 
in previous studies [4,14].
In the vehicle control experiment, 0.04% (v/v) of dimethyl 
sulfoxide, the solvent for clonidine, (the highest concentration 
in Tyrode's solution containing clonidine) had no effect on the 
current response to glutamate (0.97 ± 0.11­fold) compared with 
the control (1.00 ± 0.13­fold) (n = 10, P > 0.05). 
While clonidine itself did not induce any current in the 
oocytes injected with or without EAAT3 mRNA (data not 
shown), clonidine reduced the EAAT3 responses to L­glutamate 
(Fig. 1) in a concentration­dependent manner (7.50 × 10
-10 - 
1.88 × 10
-7 M). The IC50 value (concentration required for 50% 
inhibition) of clonidine was 2.72 × 10
-8 M. This inhibition was 
statistically significant at 2.63 × 10
-8 - 1.88 × 10
-7 M. Since 
the inhibition reached maximal at 1.50 × 10
-7 M, we used this 
concentration for further experiments. 
The Km of EAAT3 for L­glutamate was 20.2 ± 6.42 μM. This 
Km was not significantly affected by 1.50 × 10
-7 M clonidine. 
However, clonidine significantly decreased the Vmax of EAAT3 
for L­glutamate (from 1.00 ± 0.07 of control group to 0.78 ± 0.05 
of clonidine group, P < 0.05). This clonidine effect decreased 
slightly, but not significantly in the oocytes perfused with Tyrode’s 
solution for 4 min after clonidine treatment (Fig. 2).
Discussion
We demonstrated that clonidine did not have a significant 
effect on the activity of EAAT3, a major neuronal glutamate 
transporter, at clinically relevant concentrations (1.88 × 10
-9 - 
1.50 × 10
-8 M, corresponding to 0.5-4 ng/ml), but that clonidine 
concentration­dependently reduced the EAAT3 activity signifi­
cantly at higher concentrations (2.63 × 10
-8 - 1.88 × 10
-7 M, 
corresponding to 7-50 ng/ml).  
EAATs are sodium co­transporters. They co­transport two 
or three sodium ions with one negatively charged glutamate 
molecule into the cell. Thus, at least one net positive charge 
enters the cell per glutamate transported. Thus, the transport 
of glutamate is electrogenic, and the size of the glutamate­
induced current reflects the amount of glutamate transported. 
Therefore, measuring the glutamate­induced currents has been 
used widely in the literature to quantify EAAT activity [15]. 
Considerable evidence suggests that volatile, intravenous and 
local anesthetics may affect the EAAT3 activity [6­9,16].
Clonidine is an imidazoline derivate and a mixed α1 and α2 
adrenoreceptor agonist with a predominant α2 action [17]. More 
recently, clonidine has been assuming greater importance as 
an anesthetic adjuvant because of its sedative, anxiolytic and 
analgesic properties in adult and pediatric practice [10]. The 
sedative/anesthetic­sparing properties of α2­adrenergic agonists 
are ascribable to the actions in the locus ceruleus, which is 
associated with a variety of physiologic regulatory processes, 
including regulation of sleep and wakefulness [17]. 
Arenas­López et al. [18] demonstrated a consistent and 
adequate level of sedation in the majority of cases at clonidine 
plasma concentrations of 0.9-2.5 ng/ml. Sumiya et al. [19] 
reported that the plasma clonidine concentration of 0.3-0.8 
ng/ml would be sufficient to produce a satisfactory sedation 
in pediatric surgery. Clonidine is also known to be effective in 
the treatment of attention deficit­hyperactivity disorder at a 
therapeutic range of 0.5-4.5 ng/ml [20]. The exact clonidine 
concentrations around EAAT3 in the brains of patients on 
therapeutic doses of clonidine are not known. Clonidine 
crosses the blood brain barrier and the cerebrospinal fluid (CSF) 
concentration is 50% of the plasma concentration [21]. Thus, the 
therapeutic range of clonidine concentrations in the CSF may 
be lower than the clinically relevant plasma concentrations. 
Therefore, our results suggest that EAAT3 may not be a target for 
the sedative, anxiolytic, and anesthetic effects of clonidine. 
We originally expected that clonidine may increase the 
EAAT3 activity because previous studies showed that volatile 
anesthetics, benzodiazepines, propofol and lidocaine increased 
the EAAT3 activity [6­9]. However, our results showed that 
clonidine rather reduced the EAAT3 activity significantly at 2.63 
× 10
-8 - 1.88 × 10
-7 M (7-50 ng/ml). These concentrations are 
Fig. 2. Effects of clonidine on EAAT3 activity. The EAAT3 responses to 
various L-glutamate concentrations were measured before (control 
group) and immediately after clonidine treatment (clonidine group) 
and after a 4-min Tyrode’s perfusion (Tyrode’s washout). The Vmax 
and Km values of EAAT3 response to L-glutamate are listed in the 
table above the figure. Data show the means ± SEM (n = 9-17 in 
each data point). *P < 0.05 compared to the corresponding values in 
the control group.270 www.ekja.org
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higher than the clinically relevant concentrations. 
There is an apparent inconsistency in the literature con­
cerning the proconvulsant, anticonvulsant and no effects of 
clonidine [22­24]. One of the working mechanisms of clonidine 
is the down­regulation of norepinephrine release form the locus 
ceruleus. It is known that the neurotransmitter norepinephrine 
plays a relevant role in modulating seizures [25]. Although 
interactions between central norepinephrine disturbances and 
seizure susceptibility are not fully understood, there is some 
evidence that norepinephrine may act as an anticonvulsant 
via the augmentation of the inhibitory γ­aminobutyric acid 
(GABA) effect [26]. The inhibition of neuronal EAATs induces 
epilepsy in rats and decreases the inhibitory post­synaptic 
current mediated by GABA in the rat hippocampus via a 
reduced synthesis of GABA because glutamate taken up by 
neuronal EAATs is a substrate for GABA synthesis [27]. Several 
studies on experimental animals indicated that the effects of 
clonidine change according to dose. Some studies have found 
an anticonvulsant effect of low­dose clonidine, whereas high 
doses decreased seizure thresholds [28,29]. Although a direct 
or indirect effect via another system(s) cannot be excluded, the 
glutamate accumulation due to a decreased EAAT3 activity may 
be suggested as one of the possibilities of the proconvulsant 
effect of clonidine. 
We also demonstrated that clonidine did not affect the Km, 
but reduced the Vmax of EAAT3 for L­glutamate, suggesting that 
clonidine does not affect the affinity of EAAT3 for L­glutamate 
but decreases the total EAAT3 available for glutamate 
transporting. This regulatory mechanism of EAAT3 is consistent 
with the previous studies with regard to other drugs, such as 
volatile anesthetics [6], propofol [7], lidocaine [8], ethanol 
[14] and amitriptyline [30]. The clonidine­induced decreased 
EAAT3 activity was slightly, but not fully, recovered after a short 
washout, indicating that the clonidine effect may be irreversible. 
We could not clarify the exact reason for this in this study. It is 
believed that further study is needed with a longer duration 
of washout to determine the reversibility of clonidine effects. 
Possible limitations of this study are that the experiment was in 
vitro and that the mRNA of the rat instead of the human mRNA 
was used. 
In conclusion, clonidine showed an insignificant effect on 
the activity of EAAT3 at clinically relevant concentrations, but 
decreased the EAAT3 activity significantly at higher concent­
rations. These results suggest that the inhibition of EAAT3 
activity is not related to the sedation effect of clonidine. 
However, these results may provide additional data for the 
possible involvement of glutamatergic hyperactivity in the 
proconvulsant effect of clonidine. 
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